2 research outputs found

    Plausible inhibitors of malaria parasite Plasmodium falciparum 3D7 ATP-dependent DNA helicase

    Get PDF
    Background: Plasmodium falciparum is a  parasite (protozoa) of humans, & the lethal species of Plasmodium that affects malaria in humans. In the lack of a medically validated malaria vaccine, nearby are merely a few inexpensive medications available for therapy. Studies of diverse enzymes used in pharmaceutical drug discovery become essential aspects. The theoretical analysis helps to screen novel drug candidates.Methods: Here we have optimized three biologically active compounds, netropsin, nogalamycin, and novobiocin, and also carried out a molecular docking study with the protein ATP-dependent DNA helicase (UvrD) Plasmodium falciparum 3D7.Results: The plasmoDB id of the designated protein is PF3D7-0514100. Our calculations show that netropsin, nogalamycin, and novobiocin can have an affinity with the Plasmodium falciparum.Conclusion: Our study also predicted that novobiocin would give a better result with this protein than netropsin and nogalamycin. The frontier molecular orbitals & electrostatic potential (MEP) maps also support the higher activity of the novobiocin compound

    Target-based virtual screening and molecular dynamics approach to identify potential antileishmanial agents through targeting UvrD-like helicase ATP-binding domain

    Get PDF
    Background: About 0.7-1.0 million people worldwide have been suffering from Leishmaniasis. It falls under a neglected tropical disease (NTD) and is transmitted by biting infected female phlebotomine sandflies. The implication of “the NTD road map: together towards 2030” in the infection-prone regions worldwide has curtailed morbidity to a greater extent. However, limited options in antileishmanial oral and topical drugs must decipher more therapeutically efficacious agents to cure and eradicate the disease. Methods: Virtual screening based on structure, docking, & molecular dynamics approaches were adopted to identify potential lead molecules against UvrD-like helicase of Leishmania donovani from the MCULE database. Lipinski rule of five, N/O atoms (1-15), number of rings (1-2), HBDs (4-5), and HBAs (5-10) were applied as initial filters of SBVS. AutoDock Vina and GROMACS packages were used for docking and MD simulations, respectively. Results: Initial filters of SBVS workflow yielded 93885 ligand hits out of 100 plus million investigational ligands. Following the toxicology test, 28 ligands were gotten that were additional reduced to molecules (17) when accepted done the BOILED Egg model of the ADME. Six molecules were shortlisted with zero violation compliance of drug-likeness further than Lipinski RO5 viz., Egan, Veber, Muegge, Ghose, & bioavailability score having ΔG (-6.7 to -7.4 kcalmol-1) lesser than reference inhibitor miltefosine (-4.9 kcalmol-1). The stability of MCULE-5754880195-0-2 was found to be greater than the known inhibitor and ligand molecules mentioned above.Conclusion:  MCULE-5754880195-0-2 has all therapeutic features by way of an admirable oral drug molecule & could be encouraging in Leishmaniasis prevention & treatment.Keywords: UvrD-like helicase; ADME; Leishmaniasis; MCULE database; SBVS; Docking; BOILED Egg; MD simulation; ATP-binding domain
    corecore